677 related articles for article (PubMed ID: 21129617)
21. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
22. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
24. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
[TBL] [Abstract][Full Text] [Related]
25. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
26. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
27. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
28. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
29. Progress in the treatment of neuroendocrine tumors.
Chan JA; Kulke MH
Curr Oncol Rep; 2009 May; 11(3):193-9. PubMed ID: 19336011
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
31. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
Toumpanakis C; Caplin ME
Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
[TBL] [Abstract][Full Text] [Related]
32. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
33. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
34. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
35. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
Dimou A; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
[TBL] [Abstract][Full Text] [Related]
36. [Advanced renal carcinomas with special situations. How to treat them?].
Pouessel D; Patard JJ; Culine S
Bull Cancer; 2010; 97():83-90. PubMed ID: 20418207
[TBL] [Abstract][Full Text] [Related]
37. Perspectives in the development of novel treatment approaches.
Yao JC; Catena L; Colao A; Paganelli G
Tumori; 2010; 96(5):858-73. PubMed ID: 21302643
[No Abstract] [Full Text] [Related]
38. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
Khagi S; Saif MW
Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
40. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
